Abstract
There is increasing evidence reporting that as a common phenomenon in MetS relative diseases, insulin resistance (IR) is regarded as an independent etiological factor and a warning indicator of MetS occurrence. Therefore, for the special group (overweight or obesity), clinical regular monitoring of IR is an important basis for the prevention and early intervention of MetS relative diseases. This surveys reveals that human umbilical cord mesenchymal stem cells (HUC-MSCs)possess a kind of potential: it may become a possible theraphy for IR in type 2 diabetes mellitus (T2DM) and related diseases. Specific emphasis is focused on evaluating the improvement IR function of HUC-MSCs under the background of development in vitro and in vivo. Next, the action mechanisms of HUC-MSCs is discussed, and some of their advantages and disadvantages in the course of clinic application are presented. The final section highlights the application of HUC-MSCs in T2DM and relative diseases at this stage. Up to now, although many questions remain unresolved, we still consider that HUC-MSCs is one of the best therapy ameliorating IR in the future.
Keywords: Human umlilical cord mesenchymal stem cells, insulin resistance, T2DM, clinical implication, overweight, obesity.
Current Stem Cell Research & Therapy
Title:Human Umbilical Cord Mesenchymal Stem Cells Therapy for Insulin Resistance: A Novel Strategy in Clinical Implication
Volume: 13 Issue: 8
Author(s): Sheng Bi, Qing Nie, Wei-qun Wang, Yan-li Zhu, Xue-mei Ma, Chun-min Wang, Bao-cheng Zhang, Han-yang Li, Qiang Zhang* Guang Chen*
Affiliation:
- College of Public Health, Jiamusi University, Jiamusi,China
- College of Basic Medicine, Jiamusi University, Jiamusi,China
Keywords: Human umlilical cord mesenchymal stem cells, insulin resistance, T2DM, clinical implication, overweight, obesity.
Abstract: There is increasing evidence reporting that as a common phenomenon in MetS relative diseases, insulin resistance (IR) is regarded as an independent etiological factor and a warning indicator of MetS occurrence. Therefore, for the special group (overweight or obesity), clinical regular monitoring of IR is an important basis for the prevention and early intervention of MetS relative diseases. This surveys reveals that human umbilical cord mesenchymal stem cells (HUC-MSCs)possess a kind of potential: it may become a possible theraphy for IR in type 2 diabetes mellitus (T2DM) and related diseases. Specific emphasis is focused on evaluating the improvement IR function of HUC-MSCs under the background of development in vitro and in vivo. Next, the action mechanisms of HUC-MSCs is discussed, and some of their advantages and disadvantages in the course of clinic application are presented. The final section highlights the application of HUC-MSCs in T2DM and relative diseases at this stage. Up to now, although many questions remain unresolved, we still consider that HUC-MSCs is one of the best therapy ameliorating IR in the future.
Export Options
About this article
Cite this article as:
Bi Sheng , Nie Qing , Wang Wei-qun , Zhu Yan-li , Ma Xue-mei , Wang Chun-min , Zhang Bao-cheng , Li Han-yang , Zhang Qiang *, Chen Guang *, Human Umbilical Cord Mesenchymal Stem Cells Therapy for Insulin Resistance: A Novel Strategy in Clinical Implication, Current Stem Cell Research & Therapy 2018; 13 (8) . https://dx.doi.org/10.2174/1574888X13666180810154048
DOI https://dx.doi.org/10.2174/1574888X13666180810154048 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry A Review on Genus Alseodaphne: Phytochemistry and Pharmacology
Mini-Reviews in Organic Chemistry Cerebral Small Vessel Disease is Associated with Genetic Variations in CYP2J
Current Neurovascular Research Clozapine Safety, 35 Years Later
Current Drug Safety Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments
Current Pharmaceutical Design A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions
Current Pharmaceutical Design Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage
Current Drug Targets Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology An Exceptional Case of Atrial Fibrillation Arrhythmia Induced by Etoposide
Current Drug Safety Marine-Derived Bioactive Peptides as New Anticoagulant Agents: A Review
Current Protein & Peptide Science Effect of Cardiovascular Injury on Catabolism of Adenosine and Adenosine 5-‘Triphosphate in Systemic Blood in a Freely Moving Rat Model In Vivo
Drug Metabolism Letters Interrelationships between Hepatic Fat and Insulin Resistance in Non- Alcoholic Fatty Liver Disease
Current Diabetes Reviews Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology